



ČESKÁ ASOCIACE INTERVENČNÍ KARDIOLOGIE

# FAME-3

Petr Kala

FN Brno a LF MU



## ORIGINAL ARTICLE

## Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery

W.F. Fearon, F.M. Zimmermann, B. De Bruyne, Z. Piroth, A.H.M. van Straten, L. Szekely, G. Davidavičius, G. Kalinauskas, S. Mansour, R. Kharbanda, N. Östlund-Papadogeorgos, A. Aminian, K.G. Oldroyd, N. Al-Attar, N. Jagic, J.-H.E. Dambrink, P. Kala, O. Angerås, P. MacCarthy, O. Wendler, F. Casselman, N. Witt, K. Mavromatis, S.E.S. Miner, J. Sarma, T. Engstrøm, E.H. Christiansen, P.A.L. Tonino, M.J. Reardon, D. Lu, V.Y. Ding, Y. Kobayashi, M.A. Hlatky, K.W. Mahaffey, M. Desai, Y.J. Woo, A.C. Yeung, and N.H.J. Pijls, for the FAME 3 Investigators\*

Circulation: Cardiovascular Interventions

Volume 15, Issue 11, November 2022; Pages 884-891  
<https://doi.org/10.1161/CIRCINTERVENTIONS.122.012542>



### CORONARY PHYSIOLOGIC ASSESSMENT AND IMAGINGS

#### Prognostic Value of Measuring Fractional Flow Reserve After Percutaneous Coronary Intervention in Patients With Complex Coronary Artery Disease: Insights From the FAME 3 Trial

Zsolt Piroth, MD, PhD , Hisao Otsuki, MD, Frederik M. Zimmermann, MD, Tamás Ferenci, PhD , Danielle C.J. Keulards, MD, PhD, Alan C. Yeung, MD, Nico H.J. Pijls, MD, PhD, Bernard De Bruyne, MD, PhD , William F. Fearon, MD , and on behalf of the FAME 3 Investigators

**Outcomes Based on Anatomic and Functional Significance of Complex Three-Vessel Coronary Disease: The FAME 3 Trial**

Yuhei Kobayashi, MD  
On Behalf of the FAME3 Investigators

Director, Interventional Cardiology Research  
NY Presbyterian Brooklyn Methodist Hospital

Assistant Professor  
Weill Cornell Medical College

CRF  
**TCT** SEPTEMBER 16-19, 2022  
BOSTON CONVENTION AND EXHIBITION CENTER  
BOSTON, MA


# FAME 3 Trial Hypothesis

In patients with 3V-CAD, FFR-guided PCI with a current generation DES is noninferior to CABG with respect to 1-year MACCE.



# Study Design

Investigator-initiated, multicenter, randomized, controlled study



# Patient Eligibility

## Key Inclusion Criteria

- Three vessel CAD:
  - $\geq 50\%$  diameter stenosis in 3 major epicardial vessels (visual estimation, no Left Main involvement)
  - Amenable to revascularization by both PCI and CABG (Heart Team)


## Key Exclusion Criteria

- Cardiogenic shock
- Recent STEMI (within 5 days)
- LV ejection fraction  $< 30\%$



# Primary Endpoint

MACCE (Death, MI, stroke or repeat revascularization) at 1 Year



	No. at Risk												
PCI	757	728	721	713	707	702	697	696	693	687	678	674	670
CABG	743	709	701	698	695	693	691	686	683	682	679	679	679



# Safety Endpoints

Endpoint	PCI (n=757)	CABG (n=743)	p-value
BARC Type 3-5 Bleeding	1.6%	3.8%	< 0.01
Acute Kidney Injury	0.1%	0.9%	< 0.04
Atrial Fibrillation/Arrhythmia	2.4%	14.1%	< 0.001
Definite Stent Thrombosis	0.8%	N/A	
Symptomatic Graft Occlusion	N/A	1.3%	
Rehospitalization w/in 30 days	5.5%	10.2%	< 0.001




# MACCE According to SYNTAX Score

LOW (<23)  
SYNTAX SCORE

~~INTERMEDIATE (23-32)  
SYNTAX SCORE~~

~~HIGH (>32)  
SYNTAX SCORE~~


— PCI  
- - CABG






# 1-Year MACCE Based on SYNTAX Score

**Low ( $\leq 22$ )  
SYNTAX SCORE**



**High ( $>22$ )  
SYNTAX SCORE**




**Can the functional SYNTAX score identify which high SYNTAX score patients have a good outcome with PCI?**


# Reclassification with FFR Information

## SYNTAX Score

## Number of Diseased Vessels



# MACCE According to Functional SYNTAX Score




Low	368	354	353	346	342
High	365	338	325	313	306
CABG	743	699	689	680	678

# Outcome of Deferred Lesions at 1 Year


Among all deferred lesions (n=597):

- MI rate = 0.5% (n=3)
  - Revascularization rate = 3.2% (n=19)
- 
- Related to ~~started lesions or de novo lesions~~:
    - 58% of all MIs
    - 70% of all revascularizations

# Post-PCI FFR Flowchart



# Primary Endpoint: TVF at 1 Year (Vessel-Level Analysis)



Post-PCI FFR $\leq 0.88$	367	360	355	351	345
Post-PCI FFR $> 0.88$	428	427	427	415	414

# FAME 3 - Shrnutí

- FFR-guided PCI s moderním typem DES je u pacientů s 3VD spojena s horšími výsledky oproti anatomicky vedené CABG v 1 roce.
- CABG je spojena s vyšším rizikem krvácení, FISI, AKI a krátkodobých rehospitalizací.
- PCI má stejné výsledky jako CABG u pacientů s nízkým Syntax skóre (anatomicky u 32% a funkčně u 50% pacientů).
- Post-PCI FFR s hodnotou  $>0,88$  (event.  $>0,85$ ) je spojeno s významně lepšími klinickými výsledky.
- FFR  $>0,80$  značí velmi dobrou prognózu u lézí bez revaskularizace.